VYNE Stock Risk & Deep Value Analysis
Vyne Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VYNE Stock
We analyzed Vyne Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VYNE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VYNE Risk Analysis & Red Flags
What Could Go Wrong
The impending merger with Yarrow Bioscience is expected to result in current VYNE shareholders retaining only 3% ownership, leading to near-total value destruction. If the merger fails, the company faces immediate delisting from Nasdaq and likely bankruptcy due to persistent cash burn and lack of viable assets.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Proposed merger terms imply only 3% ownership for current VYNE shareholders.
- ⚠
Repibresib gel failed Phase 2b clinical trial, reducing internal pipeline value.
- ⚠
Significant and increasing TTM net losses (-$33.67M) and negative margins.
- ⚠
Nasdaq non-compliance/delisting risk (as noted in previous analysis).
- ⚠
Analyst consensus rating is 'Reduce' with an effectively meaningless high price target for current shareholders.
Upcoming Risk Events
- 📅
Failure or unfavorable renegotiation of Yarrow merger
- 📅
Official Nasdaq delisting (if merger fails to prevent it)
- 📅
Further clinical trial failures for Yarrow's pipeline
When to Reconsider
- 🚪
Official confirmation of merger terms resulting in 3% or less ownership.
- 🚪
Any announcement of Nasdaq delisting.
- 🚪
Further deterioration in cash position or increase in burn rate.
Unlock VYNE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Vyne Therapeutics Inc (VYNE) Do?
Market Cap
$20.33M
Sector
Healthcare
Industry
Biotechnology
Employees
13
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Visit Vyne Therapeutics Inc WebsiteInvestment Thesis
There is no viable bull case for current Vyne Therapeutics Inc. shareholders seeking 10x growth. The impending merger with Yarrow Bioscience is designed to salvage the corporate entity but at the severe cost of current shareholders, who are projected to own only 3% of the combined business. This, coupled with clinical failures and persistent cash burn, makes VYNE an investment with near-zero potential for existing equity holders.
Is VYNE Stock Undervalued?
Unlock the full AI analysis for VYNE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VYNE Price Targets & Strategy
12-Month Target
$0.15
Bull Case
$1.00
Bear Case
$0.05
Valuation Basis
Implied 3% ownership of a post-merger entity with a $6.25 analyst target, adjusted for delisting risk and cash burn. (0.03 * $6.25 = ~$0.1875)
Entry Strategy
Avoid entirely for long-term investment. Extreme speculation only below $0.20, acknowledging high risk of total loss.
Exit Strategy
Sell immediately if currently holding. For speculative buys, cut losses aggressively if price drops below $0.40.
Portfolio Allocation
0% for any risk tolerance due to near-total value destruction for current shareholders.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is VYNE Financially Healthy?
Valuation
P/E Ratio
-0.41
Price/Book
0.11
Profitability
Gross Margin
81.03%
Operating Margin
-5219.30%
Net Margin
-4646.14%
Return on Equity
-74.15%
Revenue Growth
13.77%
EPS
$-0.62
Balance Sheet
Current Ratio
12.53
Quick Ratio
12.11
Other
Beta (Volatility)
2.01
Does VYNE Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Vyne Therapeutics Inc. has no identifiable economic moat. Its original assets have shown clinical failure, and its future is dependent on another entity's pipeline, which it will only partially own. Any potential moat (e.g., intellectual property) would reside with the merged Yarrow entity, not with current VYNE shareholders.
Moat Erosion Risks
- •Clinical trial failures of Yarrow's pipeline.
- •Intense competition in biotech sector.
- •Loss of remaining internal IP value or talent.
VYNE Competitive Moat Analysis
Sign up to see competitive advantages
VYNE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (likely reflecting investor despair over impending dilution and operational failures).
Institutional Sentiment
Negative (previous plummeting institutional ownership; current analyst rating is 'Reduce').
Insider Activity (Form 4)
Neutral to Negative (Only tax-withholding dispositions by CEO, CFO, CLO, CSO in March 2026; no open-market purchases despite low share price).
Options Flow
Normal options activity (no specific data provided to indicate unusual institutional positioning).
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Low
Historical Earnings Pattern
Likely volatile and negative stock price reactions due to persistent losses, pipeline setbacks, and existential corporate actions.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (company undergoing an effective acquisition)
Market Share Trend
Losing (company is divesting assets, current operations are shrinking).
Valuation vs Peers
Trading at a deep discount on P/B (0.11), but this reflects a failing business model and impending dilution, not true undervaluation relative to healthy biotech peers.
Competitive Advantages
- •None for current VYNE (original pipeline failing or being de-emphasized).
- •Potential IP of Yarrow's YB-101 (only relevant for the highly diluted post-merger entity).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive VYNE Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Announcement (May 7, 2026)
- •Completion of Yarrow Merger & S-4 Filing Progression
- •Nasdaq delisting resolution (likely tied to merger)
Medium-Term (6-18 months)
- •Initial clinical data for Yarrow's YB-101 (post-merger)
- •Integration and strategic alignment of combined entity
Long-Term (18+ months)
- •Successful development and commercialization of Yarrow's pipeline candidates
- •Significant market penetration for YB-101 in Graves' disease/TED
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VYNE?
- ✓
Any material changes to the proposed merger terms (unlikely to be significantly favorable).
- ✓
Official notice regarding Nasdaq listing status.
- ✓
Updates on Yarrow's YB-101 pipeline development, though impact on VYNE shares will be minimal.
Bull Case Analysis
See what could go right with Premium
Competing with VYNE
See how Vyne Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vyne Therapeutics Inc VYNE | $20.3M | 0.6 | -0.4 | $570,000 | -4646.1% | 13.8% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Vyne Therapeutics Inc Makes Money
Vyne Therapeutics Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated inflammatory diseases. However, its current business model is primarily centered around a strategic merger with Yarrow Bioscience as a means of corporate survival. In this transaction, Vyne effectively becomes a shell that transfers its remaining assets and cash in exchange for a highly diluted stake in Yarrow's pipeline. Any future revenue or value generation will be contingent upon the success of Yarrow's lead candidate, YB-101, for Graves' disease and thyroid eye disease, rather than Vyne's original therapeutic programs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Vyne Therapeutics Inc (VYNE)?
As of April 20, 2026, Vyne Therapeutics Inc has a DVR Score of 0.6 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vyne Therapeutics Inc?
Vyne Therapeutics Inc's market capitalization is approximately $20.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Vyne Therapeutics Inc use?
VYNE is the ticker symbol for Vyne Therapeutics Inc. The company trades on the NCM.
What is the risk level for VYNE stock?
Our analysis rates Vyne Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of VYNE?
Vyne Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -0.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Vyne Therapeutics Inc's revenue growing?
Vyne Therapeutics Inc has reported revenue growth of 13.8%. The company is showing strong top-line momentum.
Is VYNE stock profitable?
Vyne Therapeutics Inc has a profit margin of -4646.1%. The company is currently unprofitable.
How often is the VYNE DVR analysis updated?
Our AI-powered analysis of Vyne Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VYNE (Vyne Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.